Dopamine receptor activation increases HIV entry into primary human macrophages

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Gaskill, Peter J ^a   Yano, Hideaki H ^b,c   Kalpana, Ganjam V ^a   Javitch, Jonathan A ^b   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHEMOKINE RECEPTOR CCR5; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; FLUPENTIXOL; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; AMIDE; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; QUATERNARY AMMONIUM DERIVATIVE;

ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN R5); INOCULATION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS CONCENTRATION; VIRUS ENTRY; VIRUS PATHOGENESIS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE; VIROLOGY;

AMIDES; CCR5 RECEPTOR ANTAGONISTS; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUPENTHIXOL; GENE EXPRESSION; HIV FUSION INHIBITORS; HIV-1; HUMANS; MACROPHAGES; PRIMARY CELL CULTURE; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; VIRUS INTERNALIZATION;

EID: 84907510723     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108232     Document Type: Article

References (166)

1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, et al. (2012) Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection. J Infect Dis 206: 275-282.
2. Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10: 350-357.
3. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
4. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
5. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, et al. (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24: 1243-1250.
6. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, et al. (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 21: 706-713.
7. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, et al. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093.
8. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, et al. (1996) Localization of HIV-1 in human brain using polymerase chain reaction/ in situ hybridization and immunocytochemistry. Ann Neurol 39: 705-711.
9. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, et al. (2001) Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193: 905-915.
10. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, et al. (2014) Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders. Curr HIV Res.
11. Eugenin EA, Berman JW (2007) Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J Neurosci 27: 12844-12850.
12. Churchill MJ,Wesselingh SL, Cowley D, Pardo CA, McArthur JC, et al. (2009) Extensive astrocyte infection is prominent in human immunodeficiency virusassociated dementia. Ann Neurol 66: 253-258.
13. Koppensteiner H, Brack-Werner R, Schindler M (2012) Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology 9: 82.
14. Yadav A, Collman RG (2009) CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 4: 430-447.
15. Hult B, Chana G, Masliah E, Everall I (2008) Neurobiology of HIV. Int Rev Psychiatry 20: 3-13.
16. Williams KC, Hickey WF (2002) Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25: 537-562.
17. Churchill M, Nath A (2013) Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 8: 165-169.
18. Thompson KA, Cherry CL, Bell JE, McLean CA (2011) Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol 179: 1623-1629.
19. Brabers NA, Nottet HS (2006) Role of the pro-inflammatory cytokines TNFalpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 36: 447-458.
20. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE (2009) A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 64: 133-145.
21. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
22. Olive MF, Taylor Lewis (2013) The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Substance Abuse and Rehabilitation: 29.
23. Papakostas GI (2006) Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 16: 391-402.
24. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, et al. (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21: RC121.
25. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, et al. (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 101: 85-91.
26. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, et al. (2004) Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol 107: 216-226.
27. Aylward EH, Brettschneider PD, McArthur JC, Harris GJ, Schlaepfer TE, et al. (1995) Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 152: 987-994.
28. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, et al. (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43: 2099-2104.
29. Navia BA, Jordan BD, Price RW (1986) The AIDS dementia complex: I. Clinical features. Ann Neurol 19: 517-524.
30. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991) Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82: 39-44.
31. Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14: 214-221.
32. Purohit V, Rapaka R, Shurtleff D (2011) Drugs of abuse, dopamine, and HIVassociated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44: 102-110.
33. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
34. Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217.
35. Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, et al. (2013) D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms. Mol Pharmacol 84: 190-200.
36. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, et al. (2009) Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 106: 21377-21382.
37. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, et al. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 104: 654-659.
38. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, et al. (2009) Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 175: 1148-1159.
39. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
40. Arai H, Charo IF (1996) Differential regulation of G-protein-mediated signaling by chemokine receptors. J Biol Chem 271: 21814-21819.
41. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-5703.
42. Tobiume M, Lineberger JE, Lundquist CA, Miller MD, Aiken C (2003) Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol 77: 10645-10650.
43. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, et al. (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73: 2343-2349.
44. Hazleton JE, Berman JW, Eugenin EA (2012) Purinergic receptors are required for HIV-1 infection of primary human macrophages. J Immunol 188: 4488-4495.
45. Cavrois M, De Noronha C, Greene WC (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20: 1151-1154.
46. Li W, Yu M, Bai L, Bu D, Xu X (2006) Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells. J Acquir Immune Defic Syndr 43: 516-522.
47. Naif HM, Li S, Ho-Shon M, Mathijs JM, Williamson P, et al. (1997) The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J Immunol 158: 501-511.
48. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM (1998) Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol 72: 4962-4969.
49. Wang J, Crawford K, Yuan M, Wang H, Gorry PR, et al. (2002) Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis 185: 885-897.
50. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, et al. (1998) Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 187: 439-444.
51. Sartori E, Calistri A, Salata C, Del Vecchio C, Palu G, et al. (2011) Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages. Virol J 8: 166.
52. Gabuzda D, Wang J (1999) Chemokine receptors and virus entry in the central nervous system. J Neurovirol 5: 643-658.
53. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, et al. (2004) Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol 78: 6915-6926.
54. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R (2011) HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 7: e1002286.
55. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The betachemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148.
56. Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, et al. (2011) Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol 85: 10669-10681.
57. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
58. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, et al. (1997) Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J Virol 71: 3219-3227.
59. Verani A, Pesenti E, Polo S, Tresoldi E, Scarlatti G, et al. (1998) CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4- dependent primary HIV-1 isolates. J Immunol 161: 2084-2088.
60. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, et al. (2001) Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 75: 10073-10089.
61. Hasko G, Szabo C, Nemeth ZH, Deitch EA (2002) Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a betaadrenoceptor- mediated mechanism. J Neuroimmunol 122: 34-39.
62. Lin Y, Quartermain D, Dunn AJ, Weinshenker D, Stone EA (2008) Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation. Synapse 62: 516-523.
63. Seeman P, Corbett R, Van Tol HH (1998) Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism. Adv Pharmacol 42: 478-482.
64. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, et al. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-619.
65. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, et al. (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
66. Arthos J, Rubbert A, Rabin RL, Cicala C, Machado E, et al. (2000) CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. J Virol 74: 6418-6424.
67. Lee C, Liu QH, Tomkowicz B, Yi Y, Freedman BD, et al. (2003) Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J Leukoc Biol 74: 676-682.
68. Harmon B, Ratner L (2008) Induction of the G q Signaling Cascade by the Human Immunodeficiency Virus Envelope Is Required for Virus Entry. Journal of Virology 82: 9191-9205.
69. Dai R, Ali MK, Lezcano N, Bergson C (2008) A crucial role for cAMP and protein kinase A in D1 dopamine receptor regulated intracellular calcium transients. Neurosignals 16: 112-123.
70. Fregeau MO, Carrier M, Guillemette G (2013) Mechanism of dopamine D2 receptor-induced Ca(2+) release in PC-12 cells. Cell Signal 25: 2871-2877.
71. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A (2011) Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.
72. Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature 341: 197-205.
73. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, et al. (1990) Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 255: 756-768.
74. Fujimura RK, Goodkin K, Petito CK, Douyon R, Feaster DJ, et al. (1997) HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia. J Acquir Immune Defic Syndr Hum Retrovirol 16: 146-152.
75. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 99: 376-384.
76. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS (2010) Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 177: 355-361.
77. Gaskill PJ, Carvallo L, Eugenin EA, Berman JW (2012) Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation 9: 203.
78. Gaskill PJ, Calderon TM, Coley JS, Berman JW (2013) Drug Induced Increases in CNS Dopamine Alter Monocyte, Macrophage and T Cell Functions: Implications for HAND. J Neuroimmune Pharmacol.
79. Wightman RM, Robinson DL (2002) Transient changes in mesolimbic dopamine and their association with 'reward'. J Neurochem 82: 721-735.
80. Garris PA, Ciolkowski EL, Pastore P, Wightman RM (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14: 6084-6093.
81. Garris PA, Wightman RM (1994) In vivo voltammetric measurement of evoked extracellular dopamine in the rat basolateral amygdaloid nucleus. J Physiol 478 ( Pt 2): 239-249.
82. Spuhler IA, Hauri A (2013) Decoding the dopamine signal in macaque prefrontal cortex: a simulation study using the Cx3Dp simulator. PLoS One 8: e71615.
83. Wightman PAGRM (1995) Voltammetric Methods in Brain Systems. Neuromethods. Totowa, New Jersey: Humana Press. 349.
84. Girault JA, Greengard P (2004) The neurobiology of dopamine signaling. Arch Neurol 61: 641-644.
85. Venton BJ, Zhang H, Garris PA, Phillips PEM, Sulzer D, et al. (2003) Realtime decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. Journal of Neurochemistry 87: 1284-1295.
86. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 30: 6975-6983.
87. Rice ME, Patel JC, Cragg SJ (2011) Dopamine release in the basal ganglia. Neuroscience 198: 112-137.
88. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278.
89. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13: 177-184.
90. Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, et al. (2010) Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [(1)(1)C]raclopride. Biol Psychiatry 68: 689-696.
91. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, et al. (2012) Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 71: 677-683.
92. Xi ZX, Kleitz HK, Deng X, Ladenheim B, Peng XQ, et al. (2009) A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. Neuroscience 161: 392-402.
93. Zachek MK, Takmakov P, Park J, Wightman RM, McCarty GS (2010) Simultaneous monitoring of dopamine concentration at spatially different brain locations in vivo. Biosens Bioelectron 25: 1179-1185.
94. Luscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69: 650-663.
95. Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69: 628-649.
96. Volkow ND, Wang GJ, Fowler JS, Tomasi D (2012) Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 52: 321-336.
97. Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME (2001) Dopaminemediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J Neurophysiol 85: 1761-1771.
98. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Zhang WB, Agnati LF (2013) Volume transmission and its different forms in the central nervous system. Chin J Integr Med 19: 323-329.
99. Lee T, Cai LX, Lelyveld VS, Hai A, Jasanoff A (2014) Molecular-level functional magnetic resonance imaging of dopaminergic signaling. Science 344: 533-535.
100. Stamford JA, Kruk ZL, Palij P, Millar J (1988) Diffusion and uptake of dopamine in rat caudate and nucleus accumbens compared using fast cyclic voltammetry. Brain Res 448: 381-385.
101. Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27: 270-277.
102. Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev 58: 303-313.
103. Vizi ES, Fekete A, Karoly R, Mike A (2010) Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br J Pharmacol 160: 785-809.
104. Trueta C, De-Miguel FF (2012) Extrasynaptic exocytosis and its mechanisms: a source of molecules mediating volume transmission in the nervous system. Front Physiol 3: 319.
105. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108: 15037-15042.
106. Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M (2003) Dopamine mediation of positive reinforcing effects of amphetamine in stimulant nai#x0308;ve healthy volunteers: results from a large cohort. European Neuropsychopharmacology 13: 459-468.
107. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, et al. (2012) Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci 32: 841-849.
108. Zhang L, Dong Y, Doyon WM, Dani JA (2012) Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. Biol Psychiatry 71: 184-191.
109. Grace AA (1995) The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 37: 111-129.
110. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, et al. (2007) Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164: 622-629.
111. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
112. Gabuzda D, Wang J (2000) Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. J Neurovirol 6 Suppl 1: S24-32.
113. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, et al. (2002) Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology 76: 6277-6292.
114. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
115. Martin-Garcia J, Cao W, Varela-Rohena A, Plassmeyer ML, Gonzalez- Scarano F (2006) HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology 346: 169-179.
116. Lewin SR, Sonza S, Irving LB, McDonald CF, Mills J, et al. (1996) Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. AIDS Res Hum Retroviruses 12: 877-883.
117. Dick AD, Pell M, Brew BJ, Foulcher E, Sedgwick JD (1997) Direct ex vivo flow cytometric analysis of human microglial cell CD4 expression: examination of central nervous system biopsy specimens from HIV-seropositive patients and patients with other neurological disease. AIDS 11: 1699-1708.
118. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, et al. (2002) Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 13: 723-737.
119. de Voux A, Chan MC, Folefoc AT, Madziva MT, Flanagan CA (2013) Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion. PLoS One 8: e54532.
120. Salimi H, Roche M, Webb N, Gray LR, Chikere K, et al. (2012) Macrophagetropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol.
121. Flanagan CA (2014) Receptor Conformation and Constitutive Activity in CCR5 Chemokine Receptor Function and HIV Infection. Adv Pharmacol 70: 215-263.
122. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, et al. (1988) Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167: 1428-1441.
123. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, et al. (1991) Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and - defective viral genomes. J Virol 65: 3973-3985.
124. Hasbi A, O'Dowd BF, George SR (2011) Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. Mol Brain 4: 26.
125. Melar M, Ott DE, Hope TJ (2007) Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux. J Virol 81: 1773-1785.
126. Liu QH, Williams DA, McManus C, Baribaud F, Doms RW, et al. (2000) HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A 97: 4832-4837.
127. Stehno-Bittel L, Krapivinsky G, Krapivinsky L, Perez-Terzic C, Clapham DE (1995) The G protein beta gamma subunit transduces the muscarinic receptor signal for Ca2+ release in Xenopus oocytes. J Biol Chem 270: 30068-30074.
128. Bonaventura J, Rico AJ,Moreno E, Sierra S, Sanchez M, et al. (2014) l-DOPAtreatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79: 90-100.
129. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5: 688-695.
130. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, et al. (2008) Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 27: 2293-2304.
131. Fuxe K, Canals M, Torvinen M, Marcellino D, Terasmaa A, et al. (2007) Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J Neural Transm 114: 49-75.
132. Franco R, Lluis C, Canela EI, Mallol J, Agnati L, et al. (2007) Receptorreceptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm 114: 93-104.
133. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96.
134. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, et al. (2011) Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 204: 753-760.
135. Gray F, Scaravilli F, Everall I, Chretien F, An S, et al. (1996) Neuropathology of early HIV-1 infection. Brain Pathol 6: 1-15.
136. Weber E, Morgan EE, Iudicello JE, Blackstone K, Grant I, et al. (2013) Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol 19: 65-74.
137. Substance Abuse and Mental Health Services Administration CfBHSaQ (2010) The NSDUH Report: HIV/AIDS and Substance Use. Rockville, MD.
138. Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F (2010) Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr 55 Suppl 1: S10-16.
139. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745.
140. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, et al. (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 58: 721-728.
141. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, et al. (2012) Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care 24: 1504-1513.
142. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, et al. (2007) Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 11: 185-194.
143. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, et al. (2002) Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 17: 377-381.
144. Berg KM, Wilson IB, Li X, Arnsten JH (2012) Comparison of antiretroviral adherence questions. AIDS Behav 16: 461-468.
145. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, et al. (2013) Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav 17: 142-147.
146. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, et al. (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10: 377-393.
147. Burris KD (2002) Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors. Journal of Pharmacology and Experimental Therapeutics 302: 381-389.
148. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, et al. (2001) Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91: 31-37.
149. Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Dixon LB, et al. (2007) Understanding associations between serious mental illness and HIV among patients in the VA Health System. Psychiatr Serv 58: 1165-1172.
150. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
151. Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, et al. (1992) Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med 54: 588-601.
152. Blank MB, Mandell DS, Aiken L, Hadley TR (2002) Co-occurrence of HIV and serious mental illness among Medicaid recipients. Psychiatr Serv 53: 868-873.
153. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7: 910-912.
154. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, et al. (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15: 257-274.
155. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011) Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 17: 26-40.
156. Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28: 406-409.
157. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8: 67-71.
158. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, et al. (2000) Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 23: 190-194.
159. Koutsilieri E, ter Meulen V, Riederer P (2001) Neurotransmission in HIV associated dementia: a short review. J Neural Transm 108: 767-775.
160. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, et al. (2010) Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm 117: 699-705.
161. Horn A, Scheller C, du Plessis S, Arendt G, Nolting T, et al. (2013) Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10- repeat allele which is more frequent in HIV-infected individuals. J Neural Transm 120: 1411-1419.
162. Gelman BB, Spencer JA, Holzer CE, 3rd, Soukup VM (2006) Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1: 410-420.
163. Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, et al. (1987) The metabolic pathology of the AIDS dementia complex. Ann Neurol 22: 700-706.
164. van Gorp WG, Mandelkern MA, Gee M, Hinkin CH, Stern CE, et al. (1992) Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia. J Neuropsychiatry Clin Neurosci 4: 280-287.
165. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, et al. (1996) Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 37: 1133-1141.
166. Georgiou MF, Gonenc A, Waldrop-Valverde D, Kuker RA, Ezuddin SH, et al. (2008) Analysis of the effects of injecting drug use and HIV-1 infection on 18FFDG PET brain metabolism. J Nucl Med 49: 1999-2005.